Dorow P, Tönnesmann U
Eur J Clin Pharmacol. 1984;27(2):135-9. doi: 10.1007/BF00544035.
The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis. Even the lowest dose of bisoprolol (5 mg) caused a marked, long-lasting reduction in blood pressure and heart rate. After doses exceeding 20 mg, the incidence of an exaggerated pharmacodynamic effect on heart rate (beta 1-blockade) increased with dose. At doses above 30 mg, bisoprolol showed incipient impairment of bronchomotor function (beta 2-blockade) in individual patients. It is concluded that bisoprolol exhibits high beta 1-selectivity, i.e. a wide beta 1/beta 2 split, since blockade of bronchial beta 2-receptors only occurred at doses well above the therapeutically relevant dose range. The results may not be applicable to chronic treatment.
在一项开放性急性试验中,对16例患有冠心病所致心绞痛和可逆性慢性阻塞性支气管炎的患者,研究了单次口服递增剂量的β-肾上腺素受体拮抗剂比索洛尔(5、10、15、20、30和40毫克)对血压、心率和支气管运动张力的影响。即使是比索洛尔的最低剂量(5毫克)也会导致血压和心率显著且持久地降低。剂量超过20毫克后,对心率(β1受体阻滞)的药效学效应过度增强的发生率随剂量增加。在30毫克以上的剂量时,个别患者出现比索洛尔早期支气管运动功能损害(β2受体阻滞)。得出的结论是,比索洛尔具有高β1选择性,即β1/β2分离度大,因为仅在远高于治疗相关剂量范围的剂量下才会发生支气管β2受体阻滞。这些结果可能不适用于长期治疗。